CeriBell (NASDAQ:CBLL) Sets New 52-Week High – Still a Buy?

CeriBell, Inc. (NASDAQ:CBLL) shares reached a new 52-week high on Monday . The stock traded as high as $24.44 and last traded at $24.40, with a volume of 396312 shares traded. The stock had previously closed at $23.33.

Wall Street Analyst Weigh In

CBLL has been the topic of several analyst reports. BTIG Research reiterated a “buy” rating and set a $28.00 price target on shares of CeriBell in a report on Tuesday, August 11th. Canaccord Genuity Group upped their price objective on shares of CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Finally, Weiss Ratings upgraded shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $22.00.

CeriBell Price Performance

The stock has a market cap of $936.42 million, a price-to-earnings ratio of -13.86 and a beta of 0.81. The stock has a fifty day simple moving average of $18.93 and a 200-day simple moving average of $19.09. The company has a current ratio of 9.18, a quick ratio of 8.79 and a debt-to-equity ratio of 0.16.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The business had revenue of $28.10 million for the quarter, compared to analyst estimates of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. As a group, equities research analysts expect that CeriBell, Inc. will post -1.96 EPS for the current year.

Insider Transactions at CeriBell

In other news, CEO Xingjuan Chao sold 39,000 shares of the company’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $19.90, for a total transaction of $776,100.00. Following the completion of the transaction, the chief executive officer owned 802,317 shares of the company’s stock, valued at approximately $15,966,108.30. This represents a 4.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Tpg Gp A, Llc sold 202,368 shares of the stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $20.12, for a total transaction of $4,071,644.16. Following the completion of the sale, the insider owned 3,765,054 shares of the company’s stock, valued at approximately $75,752,886.48. The trade was a 5.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 313,780 shares of company stock worth $6,241,749. 17.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On CeriBell

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in shares of CeriBell during the second quarter valued at approximately $37,657,000. Bank of New York Mellon Corp lifted its position in CeriBell by 1,945.9% in the fourth quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock worth $26,797,000 after purchasing an additional 1,162,200 shares during the period. KCM Capital Inc acquired a new stake in CeriBell during the fourth quarter worth $21,930,000. TimesSquare Capital Management LLC acquired a new stake in CeriBell during the second quarter worth $15,182,000. Finally, Royce & Associates LP bought a new stake in CeriBell in the 4th quarter valued at $11,695,000.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.